In this week’s episode, Kenneth Kennedy discusses FDA’s ongoing focus on the issuance of warning letters to firms marketing fraudulent COVID-19 products, and to manufacturers who have failed to meet certain requirements under applicable FDA Emergency Use Authorizations (EUAs), as well as what manufacturers and health care providers alike can learn from this trend.
COVID-19: FDA Warning Letters Address Fraudulent Products and Failures to Meet EUA Requirements [PODCAST]
Thursday, November 12, 2020
Current Public Notices
Published: 19 November, 2024
Published: 16 September, 2024
Published: 21 November, 2024
Published: 18 November, 2024
Published: 4 November, 2024
Published: 29 October, 2024